Marked increase in anti-HIV activity, as well as inhibitory activity against HIV entry mediated by CXCR4, linked to enhancement of the binding ability of tachyplesin analogs to CXCR4

AIDS Research and Human Retroviruses

Volumn 15, Issue 5, 1999, Pages 419-427

  Xu, Younong ^a   Tamamura, Hirokazu ^a   Arakaki, Rieko ^b   Nakashima, Hideki ^b   Zhang, Xiaoyan ^a   Fujii, Nobutaka ^a   Uchiyama, Takashi ^a   Hattori, Toshio ^a,c  

^a KYOTO UNIVERSITY   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN; POLYPHEMUSIN II; TACHYPLESIN; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS VECTOR;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; CELL CULTURE; CRYSTAL STRUCTURE; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME BINDING; FLOW CYTOMETRY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; T LYMPHOCYTE;

AMINO ACID SEQUENCE; ANTI-HIV AGENTS; ANTIBODIES, MONOCLONAL; ANTIMICROBIAL CATIONIC PEPTIDES; CELL LINE; CYTOPATHOGENIC EFFECT, VIRAL; DNA-BINDING PROTEINS; FLOW CYTOMETRY; GENETIC VECTORS; HIV INFECTIONS; HIV-1; HUMANS; LUCIFERASES; MOLECULAR SEQUENCE DATA; PEPTIDES; PEPTIDES, CYCLIC; RECEPTORS, CXCR4; VIRAL ENVELOPE PROTEINS;

EID: 0033586442     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922299311169     Document Type: Article

References (47)

1. Sodroski J, Goh WC, Rosen C, Campbell K, and Haseltine WA: Role of the HTLV-III/LAV envelope in syncytium formation and cytopathicity. Nature (London) 1986;322:470-474.
2. Kowalski M, Potz J, Basiripour L, Dorfman T, Goh WC, Terwilliger E, Dayton A, Rosen G, Haseltine W, and Sodroski J: Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1. Science 1987;237:1351-1355.
3. Moore JP, Jameson BA, Weiss RA, and Sattentau QJ: The HIV-cell fusion reaction. In: Viral Fusion Mechanisms (Betz J, ed.). CRC Press, Boca Raton, Florida, 1993, pp. 233-289.
4. Clapham PR, Weber JN, Whitby D, McIntosh K, Dalgleish AG, Maddon PJ, Deen KC, Sweet RW, and Weiss RA: Soluble CD4 blocks the infectivity of diverse strains of HIV and SIV for T cells and monocytes but not for brain and muscle cells. Nature (London) 1989;337:368-370.
5. Nakashima H, Yoshida O, Baba M, DeClercq E, and Yamamoto N: Anti-HIV activity of dextran sulphate as determined under different experimental conditions. Antiviral Res 1989;11:233-246.
6. Hattori T, Zhang X, Weiss C, Xu Y, Kubo T, Sato Y, Nishikawa S, Sakaida H, and Uchiyama T: Triazine dyes inhibit HIV-1 entry by binding to envelope glycoproteins. Microbiol Immunol 1997;41:717-724.
7. Xu Y, Murakami T, Kawase S, Uchiyama T, and Hattori T: Characterization of V3 loop-binding protein(s) of Molt-4 and U937 cells. Aids Res Hum Retroviruses 1995;11:563-570.
8. Maddon PJ, McDougal JS, Clapham PR, Dalgleish AG, Jamal S, Weiss RA, and Axel R: HIV infection does not require endocytosis of its receptor, CD4. Cell 1988;54:865-874.
9. Clapham PR, Blanc D, and Weiss RA: Specific cell surface requirements for the infection of CD4-positive cells by human immunodeficiency virus types 1 and 2 and by simian immunodeficiency virus. Virology 1991;181:703-715.
10. Broder CC, Dimitrov DS, Blumenthal R, and Berger EA: The block to HIV-1 envelope glycoprotein-mediated membrane fusion in animal cells expressing human CD4 can be overcome by a human cell component(s). Virology 1993;193:483-491.
11. Dragic T and Alizon M: Different requirements for membrane fusion mediated by the envelopes of human immunodeficiency virus types 1 and 2. J Virol 1993;67:2355-2359.
12. Feng Y, Broder CC, Kennedy PE, and Berger EA: HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996;272:872-877. [See comments].
13. Bleul CC, Farzan M, Choe H, Parolin C, Clark LI, Sodroski J, and Springer TA: The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature (London) 1996;382:829-833.
14. Oberlin E, Amara A, Bachelerie F, Bessia C, Virelizier JL, Arenzana SF, Schwartz O, Heard JM, Clark LI, Legler DF, Loetscher M, Baggiolini M, and Moser B: The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature (London) 1996;382:833-835.
15. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, and Berger EA: CC CKR5: A RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996;272:1955-1958.
16. Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD, Wu L, Mackay CR, LaRosa G, Newman W, Gerard N, Gerard C, and Sodroski J: The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996;85:1135-1148.
17. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di MP, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, and Landau NR: Identification of a major co-receptor for primary isolates of HIV-1. Nature (London) 1996;381:661-666. [See comments].
18. Doranz BJ, Rucker J, Yi Y, Smyth RJ, Samson M, Peiper SC, Parmentier M, Collman RG, and Doms RW: A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 1996;85:1149-1158.
19. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayanan C, Maddon PJ, Koup RA, Moore JP, and Paxton WA: HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature (London) 1996;381:667-673. [See comments].
20. Cocchi F, DeVico AL, Garzino DA, Arya SK, Gallo RC, and Lusso P: Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995;270:1811-1815. [See comments].
21. Dealwis C, Fernandez EJ, Thompson DA, Simon RJ, Siani MA, and Lolis E: Crystal structure of chemically synthesized [N33A] stromal cell-derived factor 1alpha, a potent ligand for the HIV-1 "fusin" coreceptor. Proc Natl Acad Sci USA 1998;95:6941-6946.
22. Schols D, Este JA, Henson G, and DeClercq E: Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4. Antiviral Res 1997;35:147-156.
23. Donzella GA, Schols D, Lin SW, Este JA, Nagashima KA, Maddon PJ, Allaway GP, Sakmar TP, Henson G, DeClercq E, and Moore JP: AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nature Med 1998;4:72-77.
24. Sumner SM, Zheng Y, Zhang YP, Twist EM, and Climie SC: Antiherpetic activities of N-alpha-acetyl-nona-D-arginine amide acetate. Drugs Exp Clin Res 1995;21:1-6.
25. Doranz BJ, Grovit FK, Sharron MP, Mao SH, Goetz MB, Daar ES, Doms RW, and O'Brien WA: A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J Exp Med 1997;186:1395-1400.
26. Tamamura H, Murakami T, Masuda M, Otaka A, Takada W, Ibuka T, Nakashima H, Waki M, Matsumoto A, Yamamoto N, and Fujii N: Structure-activity relationships of an anti-HIV peptide, T22. Biochem Biophys Res Commun 1994;205:1729-1735.
27. Nakashima H, Masuda M, Murakami T, Koyanagi Y, Matsumoto A, Fujii N, and Yamamoto N: Anti-human immunodeficiency virus activity of a novel synthetic peptide, T22 ([Tyr-5,12, Lys-7]polyphemusin II): A possible inhibitor of virus-cell fusion. Antimicrob Agents Chemother 1992;36:1249-1255.
28. 7]-polyphemusin II). Bioorg Med Chem 1998;6:231-238.
29. Murakami T, Nakajima T, Koyanagi Y, Tachibana K, Fujii N, Tamamura H, Yoshida N, Waki M, Matsumoto A, Yoshie O, Kishimoto T, Yamamoto N, and Nagasawa T: A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J Exp Med 1997;186:1389-1393.
30. 7]-polyphemusin II), with gp120 and CD4 by surface plasmon resonance. Biochim Biophys Acta 1996;1298:37-44.
31. Endres MJ, Clapham PR, Marsh M, Ahuja M, Turner JD, McKnight A, Thomas JF, Stoebenau HB, Choe S, Vance PJ, Wells TN, Power CA, Sutterwala SS, Doms RW, Landau NR, and Hoxie JA: CD4-independent infection by HIV-2 is mediated by fusin/CXCR4. Cell 1996;87:745-756.
32. Tamamura H, Matsumoto F, Sakano K, Otaka A, Ibuka T, and Fujii N: Unambiguous synthesis of stromal cell-derived factor-1 by regioselective disulfide bond formation using a DMSO-aqueous HCl system. Chem Commun 1998;151-152.
33. Landau NR, Page KA, and Littman DR: Pseudotyping with human T-cell leukemia virus type I broadens the human immunodeficiency virus host range. J Virol 1991;65:162-169.
34. Connor RI, Chen BK, Choe S, and Landau NR: Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 1995;206:935-944.
35. Collman R, Balliet JW, Gregory SA, Friedman H, Kolson DL, Nathanson N, and Srinivasan A: An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1. J Virol 1992;66:7517-7521.
36. Weiss CD and White JM: Characterization of stable Chinese hamster ovary cells expressing wild-type, secreted, and glycosylphosphatidylinositol-anchored human immunodeficiency virus type 1 envelope glycoprotein. J Virol 1993;67:7060-7066.
37. Koito A, Harrowe G, Levy JA, and Cheng MC: Functional role of the V1/V2 region of human immunodeficiency virus type 1 envelope glycoprotein gp120 in infection of primary macrophages and soluble CD4 neutralization. J Virol 1994;68:2253-2259.
38. Gendelman HE, Orenstein JM, Martin MA, Ferrua C, Mitra R, Phipps T, Wahl LA, Lane HC, Fauci AS, Burke DS, Skillman D, and Meltzer MS: Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J Exp Med 1988;167:1428-1441.
39. Pear WS, Nolan GP, Scott ML, and Baltimore D: Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 1993;90:8392-8396.
40. Pauwels R, Balzarini J, Baba M, Snoeck R, Schols D, Herdewijn P, Desmyter J, and DeClercq E: Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods 1988;20:309-321.
41. Nakashima H, Kido Y, Kobayashi N, Motoki Y, Neushul M, and Yamamoto N: Purification and characterization of an avian myeloblastosis and human immunodeficiency virus reverse transcriptase inhibitor, sulfated polysaccharides extracted from sea algae. Antimicrob Agents Chemother 1987;31:1524-1528.
42. 7]-polyphemusin II), which specifically blocks T cell-line-tropic HIV-1 infection. Bioorg Med Chem 1998;6:1033-1041.
43. Schols D, Struyf S, Van DJ, Este JA, Henson G, and DeClercq E: Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J Exp Med 1997;186:1383-1388.
44. Wu L, LaRosa G, Kassam N, Gordon CJ, Heath H, Ruffing N, Chen H, Humblias J, Samson M, Parmentier M, Moore JP, and Mackay CR: Interaction of chemokine receptor CCR5 with its li-gands: Multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J Exp Med 1997;186: 1373-1381.
45. McKnight A, Wilkinson D, Simmons G, Talbot S, Picard L, Ahuja M, Marsh M, Hoxie JA, and Clapham PR: Inhibition of human immunodeficiency virus fusion by a monoclonal antibody to a coreceptor (CXCR4) is both cell type and virus strain dependent. J Virol 1997;71:1692-1696.
46. Strizki JM, Turner JD, Collman RG, Hoxie J, and Gonzalez SF: A monoclonal antibody (12G5) directed against CXCR-4 inhibits infection with the dual-tropic human immunodeficiency virus type 1 isolate HIV-1 (89.6) but not the T-tropic isolate HIV-1 (HxB). J Virol 1997;71:5678-5683.
47. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, and Hendrickson WA: Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature (London) 1998;393:648-659. [See comments].